Virtual Symposium:
Oncolytic Viruses
25 May 2021 | BST (UTC+1)

The latest data & strategies impacting the development of oncolytic viruses, from discovery and biomarker development through to regulatory approval

The programme brings together international pharmaceutical organisations, leading biotech companies and globally renowned academic institutions specialising in the development of oncolytic viruses

Download Agenda

Full details on the Symposium including the presentations, topic areas and confirmed speakers will be released in the conference brochure in the coming weeks

Book Online

Full Registration is now open for Virtual Symposium: Oncolytic Viruses. Please click the button below to register for this event.

LinkedIn Group

Our LinkedIn group aims to foster discussion and collaboration between experts working in immunotherapy, autoimmunity and immuno-oncology

Virtual Symposium:
CTCs & Liquid Biopsies

is sponsored by

Programme

Benefits to Attending...

  • Hear from and meet with the leading figures in the oncolytic virus field, offering innovative case studies on the latest strategies from discovery through to the clinic
  • Interact with fellow attendees and speakers during the live Q&As, taking place at the end of each presentation and through our interactive panel discussion on ‘Understanding markers in oncolytic viruses’
  • Explore how companies are accelerating oncolytic viruses to the clinic. Presentations consider the best strategies, including combination virotherapies, likely to succeed in the clinic and deliver maximum patient benefit
  • Gain insights into how oncolytic viruses can trigger an immune response in the body against cancer, with consideration of the mechanistics of viruses, tumour biology and the tumour microenvironment

Agenda at a Glance

Morning Session:
Engineering & Translational Strategies

  • Mechanistic understanding of viruses and tumour biology
  • Engineering and optimisation strategies
  • Preclinical and translational sciences
  • Targeting the tumour microenvironment
  • Understanding markers in oncolytic viruses

Afternoon Session:
Accelerating Oncolytic Virus Immunotherapy To The Clinic

  • Clinical trial updates and challenges
  • Combination virotherapy strategies
  • Delivering oncolytic viruses into solid tumours
  • Navigating the regulatory landscape

Confirmed Speakers

The Virtual Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry perspectives.

Below are featured past speakers from our Immuno Series: 

Jochen Stritzker, Themis Bio

Jochen Strizker

Themis Bioscience GmbH

Sonia Feau, Oncorus

Sonia Feau

Oncorus

Guido Wollman, Christian Doppler

Guido Wollman

Christian Doppler Laboratory for Viral Immunotherapy of Cancer

Gianfranco di Genova

Gianfranco Di Genova

PsiOxus Therapeutics

Jose_Medina-Echeverz

Jose Medina

 Bavarian Nordic 

Event Features​

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual, remote experiences.

Virtual Presentations

Benefit from the insight of our expert speakers via live and pre-recorded presentations

Live Q&As

Interact with fellow attendees and speakers during the live Q&As at the end of each presentation

Digital Networking Opportunities

Connect directly with other event registrants around the world